Treprostinil and Abrocitinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abrocitinib
Treprostinil
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been prescribed abrocitinib (Cibinqo) for eczema and treprostinil for your lung and heart condition. Here's the concern: abrocitinib can affect your platelets (the cells that help your blood clot), especially in the first few months of treatment. Treprostinil also makes it harder for platelets to stick together. Put together, they can raise your risk of bleeding, like easy bruising, nosebleeds, or bleeding that's slow to stop.
Because of this, using both together during the early months of abrocitinib is generally something doctors avoid. Please don't stop either medicine on your own. Talk with your pharmacist or doctor so they can pick the safest plan for you.
Effect: Additive antiplatelet activity increasing bleeding risk (pharmacodynamic, not metabolic; neither agent is affected by the other's clearance here).
- Mechanism: Abrocitinib can impair platelet function; treprostinil (a prostacyclin analog) inhibits platelet aggregation. Effects on hemostasis are additive.
- Direction: Increased bleeding risk (enhanced PD effect).
- Severity: Labeled contraindicated with antiplatelet agents (other than low-dose aspirin, 81 mg/day or less) during the first 3 months of abrocitinib therapy.
- Evidence: Theoretical. Onset: unspecified.
- Management: Avoid concomitant use in the first 3 months; if unavoidable, individualize therapy and monitor for bleeding.
What happens
Increased risk of bleeding
Interaction Deep Dive
During the initial 3 months of therapy, giving abrocitinib together with antiplatelet drugs is contraindicated because of a heightened bleeding risk, with the exception of low-dose aspirin (81 mg per day or less)1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
What your care team may do:
- Avoid combining these two during the first 3 months of abrocitinib, since the label treats this pairing as contraindicated (low-dose aspirin at 81 mg or less is the exception).
- Consider timing, choosing an alternative, or watching you more closely for bleeding if both are truly needed.
What you should do:
- Keep taking both exactly as prescribed until your team advises otherwise. Do not stop on your own.
- Tell your pharmacist or prescriber that you take both, and report unusual bruising, nosebleeds, blood in urine or stool, or bleeding that won't stop.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Treprostinil and Abrocitinib together?
Combining abrocitinib and treprostinil raises bleeding risk and is generally avoided during the first 3 months of abrocitinib; don't stop either drug on your own, but talk to your pharmacist or doctor promptly. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Treprostinil and Abrocitinib interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Treprostinil and Abrocitinib interaction managed?
What your care team may do: Avoid combining these two during the first 3 months of abrocitinib, since the label treats this pairing as contraindicated (low-dose aspirin at 81 mg or less is the exception). Consider timing, choosing an alternative, or watching you more closely for bleeding if both are truly needed. What you should do: Keep taking both exactly as prescribed until your team advises ot… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Treprostinil or Abrocitinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: CIBINQO(TM) oral tablets, abrocitinib oral tablets. Pfizer Labs (per FDA), New York, NY, 2022. DailyMed
Keep reading about Abrocitinib
Keep reading about Treprostinil
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist